Advanced Therapy Medicinal Products (ATMPs) are revolutionary medicines based on cells, tissues, or genes. These therapies offer new possibilities for treating a wide range of severe diseases, from cancer to Parkinson's disease and diabetes. However, making these advanced treatments accessible to all remains a significant challenge.

The National ATMP Research School is a collaborative effort among five leading universities in Sweden: Lund University, Umeå University, Uppsala University, Karolinska Institutet, and the University of Gothenburg and is open to all Swedish higher education institutions. Together, we aim to advance the ATMP research field and create a sustainable educational platform that enables collaboration among academic, healthcare, and industry sectors, benefiting both professionals and society.

Our courses are designed to expand on standard doctoral offerings, providing new and relevant content jointly developed by our partner universities. These courses cover the entire spectrum of advanced therapy development, from initial research to clinical application.

By fostering connections between internationally recognized research environments and stakeholders in the Swedish ATMP ecosystem, we are working towards our vision of enabling patient access to ATMPs in Sweden.